Comparison of Financial Hardship and Healthcare Utilizations Associated with Cancer in the United States Medicare Programs during the COVID-19 Pandemic.

Healthcare (Basel)

Department of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, FL 32611, USA.

Published: May 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: In the United States, Medicare beneficiaries diagnosed with cancer often face significant financial challenges due to the expensive nature of cancer treatments and increased cost-sharing responsibilities. However, there is limited knowledge regarding the financial hardships and healthcare utilizations faced by those enrolled in Medicare Advantage (MA) compared to those in traditional fee-for-service Medicare (TM) during the COVID-19 pandemic. Our study aims to investigate the subjective financial hardships experienced by individuals enrolled in TM and MA and to determine whether these two Medicare programs exhibit differences in healthcare utilization during the pandemic.

Methods: We utilized data from the 2020-2022 National Health Interview Survey (NHIS), focusing on nationally representative samples of cancer survivors aged 65 or older. Financial hardship was categorized into three distinct groups: material (e.g., problems with medical bills), psychological (e.g., worry about paying), and behavioral (e.g., delayed care due to cost). Healthcare utilization included wellness visits (preventive care), emergency care services, hospitalizations, and telehealth. We used survey design-adjusted analysis to compare the study outcomes between MA and TM.

Results: Among a weighted sample of 4.4 million Medicare beneficiaries with cancer (mean age: 74.9), 76% were enrolled in MA plans. Cancer survivors with a college degree (59.3% vs. 49.8%) and high family income (38.2% vs. 31.1%) were more likely to enroll in MA plans. There were no significant differences in any material, psychological, or behavioral financial hardship domains between beneficiaries with MA and TM plans except forgone counseling due to cost. For healthcare utilization measures, cancer survivors in MA were more likely than those in TM to have flu vaccination (77.2% vs. 70.1%) and experience lower hospitalizations (16.0% vs. 20.0%). However, there were no differences in other health service utilizations between MA and TM.

Conclusion: While no significant differences were observed in any materialized, psychological, or behavioral financial hardships, older cancer survivors enrolled in MA plans were more likely to receive vaccinations and lower hospitalization rates during COVID-19. Although other preventive or primary care visits (i.e., wellness visits) were higher, their difference did not reach statistical significance. As MA grows in popularity, it is essential to consistently monitor and evaluate the performance and outcomes of Medicare plans for cancer survivors as we navigate the post-pandemic landscape.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11121441PMC
http://dx.doi.org/10.3390/healthcare12101049DOI Listing

Publication Analysis

Top Keywords

cancer survivors
20
financial hardship
12
financial hardships
12
healthcare utilization
12
cancer
9
healthcare utilizations
8
united states
8
states medicare
8
medicare programs
8
covid-19 pandemic
8

Similar Publications

Purpose: Despite its importance, little is known about the patterns and predictors of Survivorship Clinic attendance in head and neck cancer (HNC). We sought to determine the cumulative incidence of Survivorship Clinic attendance stratified by demographic, clinical, and socioeconomic factors, and to identify factors independently associated with attendance.

Methods: Our analysis population consisted of 2,252 patients diagnosed with primary HNC and seen at our institution's HNC Survivorship Clinic after completing treatment from 2016-2021.

View Article and Find Full Text PDF

Prospective Evaluation of Patient Priorities in HPV-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design.

Int J Radiat Oncol Biol Phys

September 2025

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Nursing, Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne,

Purpose: This study examined head and neck cancer treatment outcome priorities in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) before and 12 months (12m) after (chemo)radiotherapy ([C]RT).

Methods And Materials: Eligible patients were diagnosed with HPVOPC suitable for curative-intent primary [C]RT. Study data included responses to a modified version of the Chicago Priorities Scale (CPS-modified) and select items from the MDASI Head and Neck Cancer Module (MDASI-HN).

View Article and Find Full Text PDF

Cancer rates are on the rise and new treatments are helping people live longer with cancer, yet the questions remains: when does one consider themselves a cancer survivor and what direction does one's career need to take when diagnosed with cancer? This commentary explores how mentoring can support working individuals, such as pharmacy faculty and staff, across the three distinct phases of cancer survivorship, (1) the acute phase including testing, diagnosis, staging, and treatment; (2) the post-treatment survival phase; and (3) the permanent phase of disease-free survival. While career mentoring programs may exist for pharmacy faculty and staff across various pharmacy practice settings, there is a notable lack of structured mentoring programs available for those faculty and staff navigating a cancer diagnosis, especially as mentoring needs shift throughout these three cancer survivorship phases. Thoughtful mentoring and support can significantly enhance the personal and professional quality of life for individuals with cancer.

View Article and Find Full Text PDF

Background: Cisplatin is a commonly used chemotherapeutic across numerous cancer types that can cause neurotoxicities in patients, including peripheral sensory neuropathy, tinnitus, hearing loss, and vertigo.

Objective: We aimed to evaluate, for the first time, how genetic ancestry impacts cisplatin-induced neurotoxicities and if disparities are related to population differences in allele frequency.

Methods: In a cohort of cisplatin-treated testicular cancer survivors, relationships between genetic ancestry and neurotoxicities, medications, and lifestyle factors were assessed using logistic regression and Kruskal-Wallis tests and multiple pairwise comparisons using the Wilcoxon rank-sum test (Benjamini-Hochberg adjustment).

View Article and Find Full Text PDF